Generic SGLT2 Inhibitors and Interpreting Divergent CKD Trial Data
In "Generic SGLT2 Inhibitors and Interpreting Divergent CKD Trial Data," Dr. Haumschild turns to generic tiering strategy and how to read two differently designed CKD outcomes trials. In "Generic SGLT2 Inhibitors and Interpreting Divergent CKD Trial Data," Dr Haumschild turns to generic…